# To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07619833` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07619833](<https://clinicaltrials.gov/study/NCT07619833>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07619833

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 510 participants.

## Technical summary

Registry record NCT07619833. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 510 participants (planned count; ClinicalTrials.gov record NCT07619833, source copy `cardio:ctgov-nct07619833-2026-06-02`, retrieved 2026-10-26)
- Planned start: 2026-06 (anticipated) (ClinicalTrials.gov record NCT07619833, source copy `cardio:ctgov-nct07619833-2026-06-02`, retrieved 2026-10-26)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07619833, source copy `cardio:ctgov-nct07619833-2026-06-02`, retrieved 2026-10-26)
- Completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07619833, source copy `cardio:ctgov-nct07619833-2026-06-02`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07619833, source copy `cardio:ctgov-nct07619833-2026-06-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07619833-2026-06-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): DWP16001
- Intervention (Drug): DWC202518
- Intervention (Drug): Placebo of DWP16001
- Intervention (Drug): Placebo of DWC202518
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: ded4977035eb4f904ba8865b24f12f34809bb2c06299af736303dd53e3468e7c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
